Wockhardt, a pharmaceutical and biotechnology company, has posted a net loss of Rs.24.98 crore for the first quarter of this fiscal, the company said in a regulatory filing on Monday.
According to the standalone unaudited results submitted to the Bombay Stock Exchange (BSE), the company's profits declined by Rs.19.63 crore in the April-June quarter from a profit of Rs.5.35 crore in Q1 2014-15, a fall of 366 percent in profits.
However, total income from operations rose by Rs.29.26 crore from the last quarter.
Wockhardt clocked Rs.514.7 crore as the total income for Q1 2015-16 compared to Rs.485.44 crore in the same period last year, a rise of six percent.
Wockhardt has 12 manufacturing plants in India, Britain, Ireland and the US and employs 607 scientists in three global research centres.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app